# Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

> **NCT01926496** · PHASE4 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 485 (actual)

## Conditions studied

- Actinic Keratosis (AK)

## Interventions

- **DRUG:** Ingenol Mebutate Gel, 0.015%
- **DRUG:** Imiquimod Cream, 5%

## Key facts

- **NCT ID:** NCT01926496
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-11
- **Primary completion:** 2019-07-11
- **Final completion:** 2019-07-11
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926496, "Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01926496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*